Categories › Press Releases

Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation

ELITE PHARMACEUTICALS REPORTS SUCCESSFUL PIVOTAL BIOEQUIVALENCE STUDY FOR ABUSE-DETERRENT OXYCODONE PRODUCT ELI-201

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015

ELITE PHARMACEUTICALS ANNOUNCES NEW MANAGEMENT APPOINTMENTS
Back to top
mobile desktop